WUXI YAOMING UNITED BIOTECHNOLOGY CO. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards 2024-11-08 11:27
WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth 2024-08-20 23:05
WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones 2024-03-25 21:39
WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development 2024-01-31 10:43
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs) 2024-01-24 11:37
WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development 2024-01-03 09:28
WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange 2023-11-17 14:00
WuXi XDC Named Best CDMO Winner at 2023 World ADC Awards 2023-10-20 16:00
WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong 2023-10-18 11:00
WuXi XDC Launches New Commercial Manufacturing Facilities 2023-09-20 18:51
WuXi XDC and Boostimmune Sign MOU for Integrated Services 2023-08-11 08:30
1